MaxWell Biosystems provides solutions to advance basic neuroscience research and accelerate preclinical drug discovery.
MaxWell Biosystems has raised €3.7M across 1 funding round from 1 investor, most recently a Series A round in Dec 2020. Based in Basel, Switzerland; founded 2016; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-12-17 | Series A |
| €3.7M |
| Sensirion |
| View deal → |
